Sorafenib
HCC-S021
Phase 3 small_molecule active
Quick answer
Sorafenib for Hepatocellular Carcinoma is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active